期刊文献+

姑息性化疗在非小细胞肺癌中的疗效探究 被引量:6

The curative effect of palliative chemotherapy for non-small cell lung cancer
下载PDF
导出
摘要 目的探究姑息性化疗在晚期非小细胞肺癌中的疗效。方法选择2015年3月至2017年3月在我院治疗并随访完成的晚期非小细胞癌患者88例,根据患者家属治疗意见分为两组各44例,姑息性化疗组采用姑息性化疗治疗,常规治疗组采用常规支持治疗。评估患者近期、中期以及远期疗效。结果治疗后3个月姑息性化疗组第1秒用力呼气量(FEV1)、FEV1占预计值百分比(FEV1%)水平显著优于常规治疗组,血清癌胚抗原(CEA)、癌抗原19-9(CA19-9)、细胞角蛋白19的可溶性片段(CYFR21-1)水平显著低于常规治疗组(P<0.05),两组不良反应发生率比较,差异无统计学意义(P>0.05)。姑息性化疗治疗12个月后各项生活质量评分均显著高于常规治疗组(P<0.05)。姑息性化疗组患者存活率(59.10%)显著高于常规治疗组(34.82%),差异有统计学意义(P<0.05)。结论姑息性化疗能提升非小细胞肺癌患者生存质量,延长生存时间,值得在临床推广。 Objective To explore the curative effect of palliative chemotherapy for advanced non-small cell lung cancer.Methods A total of 88 patients with advanced non-small cell lung cancer treated in our hospital from March 2015 to March 2018 were divided into 2 groups according to the patient's condition,44 in each group.The palliative chemotherapy group was treated with palliative chemotherapy while the routine treatment group was given routine supportive treatment.The short-term,medium-term and long-term curative effect was evaluated.Results The forced expiratory volume in the first second(FEV1)and the percentage of FEV1 in the predicted value(FEV1%)in the palliative chemotherapy group after 3 months of treatment were significantly better than those in the routine treatment group.The serum carcinoembryonic antigen(CEA),cancer antigen 19-9(CA19-9)and cytokerantin-19-fragment(CYFRA21-1)levels were significantly lower than those in the routine treatment group(P<0.05).The incidence of adverse reactions in the palliative chemotherapy group during treatment was not significantly different from that in the routine treatment group(P>0.05).The quality of life scores of the palliative chemotherapy group after 12 months of treatment were significantly higher than those of the routine treatment group(P<0.05).The survival rate of the palliative chemotherapy group was significantly higher than that of the routine treatment group(P<0.05).Conclusion Palliative chemotherapy can improve the quality of life of patients with non-small cell lung cancer,and prolong their survival time.
作者 高燕 GAO Yan(Pidu District People's Hospital,Chengdu 611730,China)
出处 《实用医院临床杂志》 2020年第4期244-247,共4页 Practical Journal of Clinical Medicine
关键词 姑息性化疗 非小细胞肺癌 顺铂 Palliative chemotherapy Non-small cell lung cancer Cisplatin
  • 相关文献

参考文献12

二级参考文献113

  • 1程英俊.浅析姑息性化疗对肺癌患者生存率的影响[J].当代医药论丛,2014,12(5):67-68. 被引量:5
  • 2Soda M,Choi YL,Enomoto M,et al.Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.Nature,2007,448(7153):561-566. 被引量:1
  • 3Wong DW,Leung EL,So KK,et al.The EML4 ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.Cancer,2009,115(8):1723-1733. 被引量:1
  • 4Shaw AT,Yeap BY,Mino-Kenudson M,et al.Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.J Clin Oncol,2009,27(26):4247-4253. 被引量:1
  • 5Shaw AT.Phase 3 randomized study of crizotinib versus pemetrexed or docetaxel chemotherapy in advanced,ALK-positive NSCLC (PROFILE 1007).35th ESMO,2012,abstract LBA1. 被引量:1
  • 6全国肿瘤防治研究办公室/全国肿瘤登记中心/卫生部疾病预防控制局.2009全国肿瘤登记年报.北京:军事医学科学出版社.2010. 被引量:1
  • 7Rikova K,Guo A,Zeng Q,et al.Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.Cell,2007,131 (6):1190-1203. 被引量:1
  • 8Mitsudomi T,Suda K,Tomizawa K,et al.Clinico-pathologic features of lung cancer with EML4-ALK translocation.J Clin Oncol,2010 (suppl):abstr 10598. 被引量:1
  • 9Zhang X,Zhang S,Yang X,et al.Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.Mol Cancer,2010,9:188. 被引量:1
  • 10Wu SG,Kuo YW,Chang YL,et al.EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wildtype EGFR.J Thorac Oucol,2012,7(1):98-104. 被引量:1

共引文献242

同被引文献175

引证文献6

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部